EnVVeno Medical Corporation (NASDAQ:NVNO) | Finanzwire

Basculer en Français

9472	Companies
185370	Keywords
117721	Articles
99262	Press releases

Headlines Articles Press releases EnVVeno Medical Corporation

Home
Companies
EnVVeno Medical Corporation

BRIEF

published on 07/22/2025 at 14:50, 4 months 13 days ago

EnVVeno Medical Featured in Virtual Investor Conference

Investor Conference EnVVeno Medical Chronic Venous Insufficiency VenoValve® EnVVe®
PRESS RELEASE

published on 07/22/2025 at 14:45, 4 months 13 days ago

enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
enVVeno Medical Corporation announces the availability of on-demand video webcast featuring CEO Rob Berman discussing the Company's products and his dedication

VenoValve EnVVeno Medical Corporation Virtual Investor On-Demand Video Webcast
BRIEF

published on 06/06/2025 at 14:10, 5 months 28 days ago

EnVVeno Medical Reveals Promising Interim Results from VenoValve Study

FDA Approval Quality Of Life Chronic Venous Insufficiency Clinical Improvement VenoValve Trial
PRESS RELEASE

published on 06/06/2025 at 14:05, 5 months 28 days ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Interim two-year follow-up data from VenoValve pivotal trial show sustained clinical improvement at 24 months compared to baseline. FDA decision expected in 2025

VenoValve Venous Disease Pivotal Trial FDA Decision Interim Data
BRIEF

published on 05/19/2025 at 14:10, 6 months 16 days ago

EnVVeno Medical Appoints Jennifer Bright as CFO

Chief Financial Officer VenoValve EnVVeno Medical Corporation FDA Authorization Jennifer Bright
PRESS RELEASE

published on 05/19/2025 at 14:05, 6 months 16 days ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer
enVVeno Medical Corporation appoints Jennifer Bright as Chief Financial Officer, bringing extensive experience to support commercialization efforts and financial infrastructure

Chief Financial Officer Commercialization Financial Infrastructure EnVVeno Medical Corporation Jennifer Bright
BRIEF

published on 05/13/2025 at 14:50, 6 months 22 days ago

EnVVeno Medical's VenoValve Study Published with Positive Three-Year Results

VenoValve Chronic Venous Insufficiency FDA Application Clinical Outcomes Patency Rate
PRESS RELEASE

published on 05/13/2025 at 14:45, 6 months 22 days ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery
enVVeno Medical Corporation reports positive three-year outcomes from first-in-human study of VenoValve for deep venous disease treatment, PMA application submitted to FDA

VenoValve CVI PMA Application FDA Decision Deep Venous Disease
BRIEF

published on 05/01/2025 at 14:10, 7 months 3 days ago

EnVVeno Medical Reports Q1 2025 Financials and FDA Progress

Financial Results Market Entry VenoValve FDA Decision EnVVe Pivotal Study
PRESS RELEASE

published on 05/01/2025 at 14:05, 7 months 3 days ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24
enVVeno Medical Corporation reports $4.0 million cash burn in Q1 in line with projections. Cash position sufficient for operations post-FDA decision of VenoValve. FDA decision expected in H2 2025

Financial Results VenoValve EnVVeno Medical Corporation FDA Decision EnVVe Pivotal Trial

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 41 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 46 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 16 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 11 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 16 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 16 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 46 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 25 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 51 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 1 minute ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:00, 13 hours 16 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 31 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 32 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE